Italia markets close in 3 hours 38 minutes

JNJ Jun 2025 200.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,48000,0000 (0,00%)
In data: 10:27AM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,4800
Aperto0,5500
Denaro0,0000
Domanda0,0000
Prezzo d'esercizio200,00
Scadenza2025-06-20
Min-Max giorno0,4800 - 0,5500
Contratto - Min-MaxN/D
Volume20
Open Interest737
  • GlobeNewswire

    Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®

    According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than February 21, 2025 REYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA